Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
6 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Analyses of tumor microenvironment in patients with advanced renal cell carcinoma receiving immunotherapy (Meet-URO 18 study).
Future Oncol. 2024 Apr 29. doi: 10.2217/fon-2023-1068. Online ahead of print.
Future Oncol. 2024.
PMID: 38682738
Significance of PD-L1 in Metastatic Urothelial Carcinoma Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
Maiorano BA, Di Maio M, Cerbone L, Maiello E, Procopio G, Roviello G; MeetURO Group.
Maiorano BA, et al.
JAMA Netw Open. 2024 Mar 4;7(3):e241215. doi: 10.1001/jamanetworkopen.2024.1215.
JAMA Netw Open. 2024.
PMID: 38446479
Free PMC article.
Item in Clipboard
Apalutamide-induced lichenoid reaction in a patient with non-metastatic castrate-resistant prostate cancer.
Cremante M, Puglisi S, Gandini A, Guadagno A, Catalano F, Damassi A, Murianni V, Llaja Obispo MA, Banna GL, Buti S, Rebuzzi SE, Rescigno P, Fornarini G.
Cremante M, et al. Among authors: llaja obispo ma.
J Oncol Pharm Pract. 2023 Oct;29(7):1748-1753. doi: 10.1177/10781552231180598. Epub 2023 Jun 6.
J Oncol Pharm Pract. 2023.
PMID: 37282554
Item in Clipboard
Characterization of Tumor and Immune Tumor Microenvironment of Primary Tumors and Metastatic Sites in Advanced Renal Cell Carcinoma Patients Based on Response to Nivolumab Immunotherapy: Preliminary Results from the Meet-URO 18 Study.
Rebuzzi SE, Brunelli M, Galuppini F, Vellone VG, Signori A, Catalano F, Damassi A, Gaggero G, Rescigno P, Maruzzo M, Merler S, Vignani F, Cavo A, Basso U, Milella M, Panepinto O, Mencoboni M, Sbaraglia M, Dei Tos AP, Murianni V, Cremante M, Llaja Obispo MA, Maffezzoli M, Banna GL, Buti S, Fornarini G.
Rebuzzi SE, et al. Among authors: llaja obispo ma.
Cancers (Basel). 2023 Apr 21;15(8):2394. doi: 10.3390/cancers15082394.
Cancers (Basel). 2023.
PMID: 37190322
Free PMC article.
Item in Clipboard
A novel immunotherapy prognostic score for patients with pretreated advanced urInary TrAct CArcinoma from the subgroup analysis of the SAUL study: the ITACA Score.
Fornarini G, Rebuzzi SE, Buti S, Rescigno P, Merseburger A, Sternberg CN, de Giorgi U, Basso U, Maruzzo M, Giannatempo P, Ponzano M, Giunta EF, Catalano F, Murianni V, Damassi A, Cremante M, Gandini A, Puglisi S, Llaja Obispo MA, Signori A, Banna GL.
Fornarini G, et al. Among authors: llaja obispo ma.
Minerva Urol Nephrol. 2023 Jun;75(3):308-318. doi: 10.23736/S2724-6051.22.05135-7. Epub 2022 Dec 13.
Minerva Urol Nephrol. 2023.
PMID: 36511379
Free article.
Clinical Trial.
Item in Clipboard
The prognostic value of baseline and early variations of peripheral blood inflammatory ratios and their cellular components in patients with metastatic renal cell carcinoma treated with nivolumab: The Δ-Meet-URO analysis.
Rebuzzi SE, Signori A, Stellato M, Santini D, Maruzzo M, De Giorgi U, Pedrazzoli P, Galli L, Zucali PA, Fantinel E, Carella C, Procopio G, Milella M, Boccardo F, Fratino L, Sabbatini R, Ricotta R, Panni S, Massari F, Sorarù M, Santoni M, Cortellini A, Prati V, Soto Parra HJ, Atzori F, Di Napoli M, Caffo O, Messina M, Morelli F, Prati G, Nolè F, Vignani F, Cavo A, Roviello G, Llaja Obispo MA, Porta C, Buti S, Fornarini G, Banna GL.
Rebuzzi SE, et al. Among authors: llaja obispo ma.
Front Oncol. 2022 Sep 23;12:955501. doi: 10.3389/fonc.2022.955501. eCollection 2022.
Front Oncol. 2022.
PMID: 36212433
Free PMC article.
Item in Clipboard
Cite
Cite